- Home
- ACET vs CURR Comparison
ACET vs CURR Comparison
Compare ACET & CURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- CURR
- Stock Information
- Founded
- ACET 1947
- CURR 2013
- Country
- ACET United States
- CURR Singapore
- Employees
- ACET N/A
- CURR N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- CURR Business Services
- Sector
- ACET Health Care
- CURR Consumer Discretionary
- Exchange
- ACET Nasdaq
- CURR Nasdaq
- Market Cap
- ACET 93.1M
- CURR 89.8M
- IPO Year
- ACET N/A
- CURR N/A
- Fundamental
- Price
- ACET $0.96
- CURR $1.34
- Analyst Decision
- ACET Strong Buy
- CURR
- Analyst Count
- ACET 4
- CURR 0
- Target Price
- ACET $5.67
- CURR N/A
- AVG Volume (30 Days)
- ACET 790.0K
- CURR 10.5K
- Earning Date
- ACET 11-06-2024
- CURR 02-11-2025
- Dividend Yield
- ACET N/A
- CURR N/A
- EPS Growth
- ACET N/A
- CURR N/A
- EPS
- ACET N/A
- CURR N/A
- Revenue
- ACET N/A
- CURR $55,500,917.00
- Revenue This Year
- ACET N/A
- CURR N/A
- Revenue Next Year
- ACET N/A
- CURR N/A
- P/E Ratio
- ACET N/A
- CURR N/A
- Revenue Growth
- ACET N/A
- CURR N/A
- 52 Week Low
- ACET $0.89
- CURR $1.20
- 52 Week High
- ACET $3.77
- CURR $5.74
- Technical
- Relative Strength Index (RSI)
- ACET 37.36
- CURR N/A
- Support Level
- ACET $0.91
- CURR N/A
- Resistance Level
- ACET $1.12
- CURR N/A
- Average True Range (ATR)
- ACET 0.09
- CURR 0.00
- MACD
- ACET 0.00
- CURR 0.00
- Stochastic Oscillator
- ACET 16.21
- CURR 0.00
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants worldwide, delivering frictionless interoperable real-time fund transfers and instant messaging.